Season 4 - Ep1: Extended interview on Digital solutions in arrhythmias

Jan 22, 2026

Fleur Tjong, a cardiology expert at Amsterdam UMC specializing in digital cardiology and AI in electrophysiology, engages in a rich discussion about the future of heart health. She explores how AI can predict atrial fibrillation risks using ECG data and emphasizes personalized approaches to monitoring. Fleur also highlights the importance of integrating wearable data into electronic health records without overwhelming clinics. Additionally, she discusses training for clinicians in digital tools, the health economics of remote monitoring, and her vision for AI's role in arrhythmia care over the next five years.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

AI ECG Predicts AF Risk After Cryptogenic Stroke

AI on sinus-rhythm 12‑lead ECG can identify patients at higher risk of future atrial fibrillation after embolic stroke of undetermined origin.
Fleur Tjong cautions we should confirm AF before changing therapy but use AI to target longer monitoring.

INSIGHT

Burden Is About Patterns, Not Single Thresholds

Atrial fibrillation burden is the proportion of time a patient is in AF and depends on monitoring method and time window.
Fleur Tjong emphasizes patterns and trends (rising burden, prolonged episodes, symptom correlation) over universal thresholds.

ADVICE

Triage Wearable Alerts Before EHR Integration

Integrate device data into EHRs with targeted triage to avoid overwhelming clinics.
Establish infrastructure so only relevant, triaged alerts reach outpatient workflows.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Host: Emer Joyce

Guest: Fleur Tjong

Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview

Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528

Disclaimer:

ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

All declarations of interest are listed at the end of the episode.

The ESC is not liable for any translated content of this video. The English language always prevails.

Declarations of interests:

Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.